• Nachrichtendetail
• 

17.06.2024 14:02:15 - dpa-AFX: *J&J :SUBCUTANEOUS AMIVANTAMAB BLA SUBMITTED TO FDA FOR PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER

	Name	WKN	Börse	Kurs	Datum/Zeit	Diff.	Diff. %	Geld	Brief	Erster	Schluss
	JOHNSON + JOHNSON DL 1	853260	Xetra	137,140	27.06.24 15:29:34	-0,220	-0,16%	136,860	137,060	137,600	137,360